Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
← catalyst calendarNCT07170917 · readout in 347 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
208estimated
Sites
79
Countries
Australia, Canada, Chile +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-06 | actual | When the study began enrolling |
| Primary completion | 2027-08-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-27 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa
Interventions
- Drug: Brivekimig — also filed as SAR442970
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)
measured Up to Week 16
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed